Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results
Salarius Pharmaceuticals, Inc.May 5, 2021 GMT
HOUSTON, May 05, 2021 (GLOBE NEWSWIRE) Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 12, 2021, at 5:00 p.m. ET, to discuss its corporate and financial results for the first quarter 2021.
Conference Call Information:
(833) 423-0481 (U.S.) Conference ID: 9062629
An audio webcast will be accessible via the Investors Events and Presentations section of the Company’s website http://investors.salariuspharma.com/. An archive of the webcast will remain available for 90 days beginning at approximately 5:30 p.m. ET, on�
Message :
Required fields
HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that all three submitted abstracts detailing research involving seclidemstat were accepted for poster presentations, with one abstract also selected for a poster discussion session, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO will be held virtually from June 4-8, 2021.
“We are very pleased to report that research involving seclidemstat will be the subject of three poster presentations at the 2021 ASCO Annual Meeting,” stated David Arthur, President and CEO of Salarius Pharmaceuticals. “As previously noted, the full findings from the dose escalation-stage of the Phase 1/2 trial of seclidemstat in patients with relapsed and refractory Ewing sarcoma, including details